Vivoryon Therapeutics NV
Company Profile
Business description
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer’s disease.
Contact
Weinbergweg 22
HalleSN06120
DEUT: +49 3455559900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Shares leap for ASX rare earths provider
stocks
Does SpaceX’s sky-high valuation make sense?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.40 | 29.00 | -0.33% |
| CAC 40 | 8,010.91 | 17.42 | 0.22% |
| DAX 40 | 23,608.27 | 31.76 | -0.13% |
| Dow JONES (US) | 47,417.27 | 289.24 | -0.61% |
| FTSE 100 | 10,318.33 | 35.44 | -0.34% |
| HKSE | 25,716.76 | 182.00 | -0.70% |
| NASDAQ | 22,716.13 | 19.03 | 0.08% |
| Nikkei 225 | 54,452.96 | 572.41 | -1.04% |
| NZX 50 Index | 13,199.29 | 93.84 | -0.71% |
| S&P 500 | 6,775.80 | 5.68 | -0.08% |
| S&P/ASX 200 | 8,629.00 | 14.20 | -0.16% |
| SSE Composite Index | 4,129.10 | 4.33 | -0.10% |